mRNA合成・製造市場：2035年までの業界動向と世界の予測-製品タイプ別、応用分野別、治療分野別、主要地域別

リボ核酸（RNA）は、すべての生体細胞に存在するユビキタス分子で、遺伝情報をタンパク質に変換する役割を担っており、様々な細胞プロセスにとって重要です。RNAには、メッセンジャーRNA（mRNA）、トランスファーRNA（tRNA）、リボソームRNA（rRNA）など、さまざまな形態があり、mRNAは現代ヘルスケアにおける重要な治療手段として台頭してきています。mRNA上の遺伝暗号はアミノ酸に翻訳され、機能的なタンパク質に加工されます。COVID-19の大流行以来、mRNAワクチンと治療薬の製造は大きな注目を集め、COVID-19だけでなく、腫瘍性疾患、感染症、遺伝性疾患などさまざまな疾患に対する次世代薬剤クラスとして浮上しています。

しかし、mRNA治療薬やワクチンの製造は複雑で高価なプロセスであり、専門的な知識や能力が要求されます。そのため、mRNA治療薬やワクチンの開発者は、こうした課題を克服するための解決策を積極的に模索しています。アウトソーシングはmRNA開発者にとって魅力的な選択肢として浮上しており、こうしたハードルに対する潜在的な解決策を提供しています。今後、慢性疾患の増加、遺伝子治療に対する需要の高まり、臨床・商業段階におけるRNAベースの治療法の成熟化、技術の進歩により、mRNA合成・製造市場の堅調な成長が予想されます。

当レポートでは、世界のmRNA合成・製造市場について調査し、市場の概要とともに、製品タイプ別、応用分野別、治療分野別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 mRNAカスタム合成サービスプロバイダー：市場情勢

第7章 mRNAカスタム合成サービスプロバイダー：企業競争力分析

第8章 企業プロファイル：mRNAカスタム合成サービスプロバイダー

第9章 mRNA受託製造サービスプロバイダー：市場情勢

第10章 mRNA受託製造サービスプロバイダー：企業競争力分析

第11章 企業プロファイル：mRNA受託製造サービスプロバイダー

第12章 mRNA合成キットプロバイダー：市場情勢

第13章 mRNA合成キット：製品競争力分析

第14章 企業プロファイル：mRNA合成キットプロバイダー

第15章 パートナーシップとコラボレーション

第16章 有望パートナーの分析

第17章 大手製薬会社の取り組み

第18章 市場への影響分析：促進要因、制約要因、機会、課題

• 章の概要
• 市場の促進要因
• 市場の抑制要因
• 市場の機会
• 市場の課題

第19章 世界のmRNA合成・製造市場

• 章の概要
• 主な前提と予測調査手法
• 世界のmRNA合成・製造市場、歴史的動向（2021年～2023年）および予測（2024年～2035年）（10億米ドル）
• 主要な市場セグメンテーション

第20章 mRNA合成・製造市場、製品タイプ別

第21章 mRNA合成・製造市場、応用分野別

第22章 mRNA合成・製造市場、治療分野別

第23章 mRNA合成・製造市場、主要地域別

第24章 エグゼクティブ洞察

第25章 付録1：表形式のデータ

第26章 付録2：企業・団体一覧

List of Tables

• Table 6.1 List of mRNA Custom Synthesis Service Providers
• Table 6.2 mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Synthesized
• Table 6.3 mRNA Custom Synthesis Service Providers: Information on mRNA Production Capacity
• Table 8.1 Aldevron: mRNA Custom Synthesis Service Portfolio
• Table 8.2 TriLink Biotechnologies: mRNA Custom Synthesis Service Portfolio
• Table 8.3 etheRNA: mRNA Custom Synthesis Service Portfolio
• Table 8.4 Biomay: mRNA Custom Synthesis Service Portfolio
• Table 8.5 GenScript: mRNA Custom Synthesis Service Portfolio
• Table 8.6 Aurigene Pharmaceutical Services: mRNA Custom Synthesis Service Portfolio
• Table 9.1 List of mRNA Contract Manufacturing Service Providers
• Table 11.1 Eurogentec: mRNA Contract Manufacturing Service Portfolio
• Table 11.2 Wuxi Biologics: mRNA Contract Manufacturing Service Portfolio
• Table 11.3 Merck: mRNA Contract Manufacturing Service Portfolio
• Table 11.4 ST Pharm: mRNA Contract Manufacturing Service Portfolio
• Table 11.5 Vernal Biosciences: mRNA Contract Manufacturing Service Portfolio
• Table 11.6 Curia: mRNA Contract Manufacturing Service Portfolio
• Table 12.1 List of mRNA Synthesis Kits
• Table 12.2 List of mRNA Synthesis Kit Providers
• Table 14.1 Jena Biosciences: mRNA Synthesis Kits Portfolio
• Table 14.2 APExBIO: mRNA Synthesis Kits Portfolio
• Table 14.3 ThermoFisher Scientific: mRNA Synthesis Kits Portfolio
• Table 14.4 CELLSCRIPT: mRNA Synthesis Kits Portfolio
• Table 14.5 New England Biolabs: mRNA Synthesis Kits Portfolio
• Table 14.6 Enzynomics: mRNA Synthesis Kits Portfolio
• Table 15.1 mRNA Synthesis and Manufacturing Services: List of Partnerships and Collaborations, 2019-2023
• Table 17.1 Big Pharma Players: List of mRNA Focused Initiatives, 2019-2023
• Table 25.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
• Table 25.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
• Table 25.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
• Table 25.4 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
• Table 25.5 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
• Table 25.6 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
• Table 25.7 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
• Table 25.8 mRNA Custom Synthesis Service Providers: Distribution by Application Area
• Table 25.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
• Table 25.10 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
• Table 25.11 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
• Table 25.12 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
• Table 25.13 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
• Table 25.14 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services
• Table 25.15 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
• Table 25.16 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
• Table 25.17 mRNA Synthesis Kits: Distribution by Kit Components
• Table 25.18 mRNA Synthesis Kits: Distribution by Type of Enzymes
• Table 25.19 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
• Table 25.20 mRNA Synthesis Kits: Distribution by mRNA Component Modified
• Table 25.21 mRNA Synthesis Kits: Distribution by Number of Reactions
• Table 25.22 mRNA Synthesis Kits: Distribution by Yield per Reaction
• Table 25.23 mRNA Synthesis Kits: Distribution by Reaction Run-time
• Table 25.24 mRNA Synthesis Kits: Distribution by Price of Kits
• Table 25.25 Most Active Players: Distribution by Number of Kits Offered
• Table 25.26 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
• Table 25.27 mRNA Synthesis Kit Providers: Distribution by Company Size
• Table 25.28 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
• Table 25.29 Partnerships and Collaborations: Distribution by Year of Partnership
• Table 25.30 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 25.31 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Table 25.32 Partnerships and Collaborations: Distribution by Type of Product (Broad)
• Table 25.33 Partnerships and Collaborations: Distribution by Type of Product (Specific)
• Table 25.34 Partnerships and Collaborations: Distribution by Type of Partner
• Table 25.35 Most Active Players: Distribution by Number of Partnerships
• Table 25.36 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
• Table 25.37 Partnerships and Collaborations: Local and International Deals
• Table 25.38 Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2032) (USD Billion)
• Table 25.39 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (2024-2032) (Conservative Scenario) (USD Billion)
• Table 25.40 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (2024-2032) (Optimistic Scenario) (USD Billion)
• Table 25.41 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024, and 2035
• Table 25.42 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), till 2035 (USD Billion)
• Table 25.43 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs) till 2035 (USD Billion)
• Table 25.44 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024, and 2035
• Table 25.45 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035 (USD Billion)
• Table 25.46 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035 (USD Billion)
• Table 25.47 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2024 and 2035
• Table 25.48 mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035 (USD Billion)
• Table 25.49 mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035 (USD Billion)
• Table 25.50 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035 (USD Billion)
• Table 25.51 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2021, 2024 and 2035
• Table 25.52 mRNA Synthesis and Manufacturing Market in North America, till 2035 (USD Billion)
• Table 25.53 mRNA Synthesis and Manufacturing Market in Europe, till 2035 (USD Billion)
• Table 25.54 mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
• Table 25.55 mRNA Synthesis and Manufacturing Market in Latin America, till 2035 (USD Billion)
• Table 25.56 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
• Table 25.57 mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035 (USD Billion)

List of Figures

• Figure 2.1 Research Methodology: Project Methodology
• Figure 2.2 Research Methodology: Forecast Methodology
• Figure 2.3 Research Methodology: Robust Quality Control
• Figure 2.4 Research Methodology: Key Market Segmentations
• Figure 3.1 Lessons Learnt from Past Recessions
• Figure 4.1 Executive Summary: mRNA Custom Synthesis Service Providers Market Landscape
• Figure 4.2 Executive Summary: mRNA Contract Manufacturing Service Providers Market Landscape
• Figure 4.3 Executive Summary: mRNA Synthesis Kits Market Landscape
• Figure 4.4 Executive Summary: Partnership and Collaborations
• Figure 4.5 Executive Summary: Big Pharma Initiatives
• Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
• Figure 5.1 Structure of mRNA
• Figure 5.2 Evolution of mRNA Vaccines
• Figure 5.3 Steps involved in mRNA Synthesis
• Figure 6.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
• Figure 6.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
• Figure 6.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
• Figure 6.4 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
• Figure 6.5 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
• Figure 6.6 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
• Figure 6.7 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
• Figure 6.8 mRNA Custom Synthesis Service Providers: Distribution by Application Area
• Figure 6.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
• Figure 7.1 Company Competitiveness Analysis: mRNA Custom Synthesis Service Providers based in North America
• Figure 7.2 Company Competitiveness Analysis: Benchmarking of mRNA Custom Synthesis Service Providers in North America
• Figure 7.3 Company Competitiveness Analysis: mRNA Custom Synthesis Service Providers based in Europe
• Figure 7.4 Company Competitiveness Analysis: Benchmarking of mRNA Custom Synthesis Service Providers in Europe
• Figure 7.5 Company Competitiveness Analysis: mRNA Custom Synthesis Service Providers based in Asia-Pacific
• Figure 7.6 Company Competitiveness Analysis: Benchmarking of mRNA Custom Synthesis Service Providers in Asia-Pacific
• Figure 9.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
• Figure 9.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
• Figure 9.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)
• Figure 9.4 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)
• Figure 9.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
• Figure 9.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services
• Figure 9.7 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
• Figure 9.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
• Figure 10.1 Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
• Figure 10.2 Company Competitiveness Analysis: Benchmarking of mRNA Contract Manufacturing Service Providers in North America
• Figure 10.3 Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
• Figure 10.4 Company Competitiveness Analysis: Benchmarking of mRNA Contract Manufacturing Service Providers in Europe
• Figure 10.5 Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific
• Figure 10.6 Company Competitiveness Analysis: Benchmarking of mRNA Contract Manufacturing Service Providers in Asia-Pacific
• Figure 12.1 mRNA Synthesis Kits: Distribution by Kit Components
• Figure 12.2 mRNA Synthesis Kits: Distribution by Type of Enzyme
• Figure 12.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
• Figure 12.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
• Figure 12.5 mRNA Synthesis Kits: Distribution by Number of Reaction
• Figure 12.6 mRNA Synthesis Kits: Distribution by Yield Per Reaction
• Figure 12.7 mRNA Synthesis Kits: Distribution by Reaction Run-time
• Figure 12.8 mRNA Synthesis Kits: Distribution by Kit Price
• Figure 12.9 Most Active Players: Distribution by Number of Kits Offered
• Figure 12.10 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
• Figure 12.11 mRNA Synthesis Kit Providers: Distribution by Company Size
• Figure 12.12 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
• Figure 13.1 Product Competitiveness Analysis: mRNA Synthesis Kits
• Figure 15.1 Partnerships and Collaborations: Distribution by Year of Partnership
• Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Figure 15.4 Partnerships and Collaborations: Distribution by Type of Product (Broad)
• Figure 15.5 Partnerships and Collaborations: Distribution by Type of Product (Specific)
• Figure 15.6 Partnerships and Collaborations: Distribution by Type of Partner
• Figure 15.7 Most Active Players: Distribution by Number of Partnerships
• Figure 15.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
• Figure 15.9 Partnerships and Collaborations: Local and International Deals
• Figure 16.1 mRNA Drug Developers: Likely Partners based in North America
• Figure 16.2 mRNA Drug Developers: Most Likely Partners based in North America
• Figure 16.3 mRNA Drug Developers: Likely Partners based in Europe
• Figure 16.4 mRNA Drug Developers: Most Likely Partners based in Europe
• Figure 16.5 mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
• Figure 16.6 mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World
• Figure 17.1 Benchmarking of Big Pharma Players: Spider Web Analysis
• Figure 17.2 Big Pharma Players: Distribution by Portfolio Diversity
• Figure 17.3 Big Pharma Players: Distribution by Therapeutic Diversity
• Figure 17.4 Big Pharma Players: Distribution by Number of Initiatives
• Figure 18.1. Market Trends and Outlook: Key Growth Drivers
• Figure 18.2. Market Trends and Outlook: Market Restraints
• Figure 18.3. Market Trends and Outlook: Opportunities
• Figure 18.4. Market Trends and Outlook: Challenges
• Figure 19.1 Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
• Figure 20.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024 and 2035
• Figure 20.2 mRNA Synthesis and Manufacturing: Market for Drug Substances (APIs), till 2035
• Figure 20.3 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), till 2035
• Figure 21.1 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024 and 2035
• Figure 21.2 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035
• Figure 21.3 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035
• Figure 22.1 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2024 and 2035
• Figure 22.2 mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035
• Figure 22.3 mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035
• Figure 22.4 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035
• Figure 23.1 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2021, 2024 and 2035
• Figure 23.2 mRNA Synthesis and Manufacturing Market in North America, till 2035
• Figure 23.3 mRNA Synthesis and Manufacturing Market in Europe, till 2035
• Figure 23.4 mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035
• Figure 23.5 mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035

mRNA Synthesis and Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product (Drug Substances (APIs) and Drug Products (FDFs)), Application Area (mRNA-based Vaccines and mRNA-based Therapeutics), Therapeutic Area (Infectious Diseases, Oncological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

The mRNA Synthesis and Manufacturing Market is valued at USD 1.06 billion in 2024.

Ribonucleic acid (RNA) is a ubiquitous molecule found in all the living cells, which is responsible for translating genetic information into proteins which is important for various cellular processes. RNA comes in different forms, including messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA), with mRNA emerging as a prominent therapeutic modality in modern healthcare. mRNA is a single-stranded molecule that carries genetic information from DNA to produce proteins. This genetic code on mRNA is translated into amino acids, which are then processed into functional proteins. Since the onset of the COVID-19 pandemic, mRNA vaccine and therapeutic manufacturing have garnered considerable attention, emerging as a next-generation drug class not only for COVID-19 but also for various other conditions like oncological disorders, infectious diseases, and genetic disorders.

However, producing mRNA therapeutics and vaccines is a complex and expensive process which demands specialized expertise and capabilities. Consequently, developers of mRNA therapeutics and vaccines are actively exploring solutions to overcome these challenges. Outsourcing has emerged as an attractive option for mRNA developers, offering potential solutions to these hurdles. Looking ahead, with the increasing prevalence of chronic diseases, growing demand for gene therapy, maturation of RNA-based therapies in clinical and commercial stages, and advancements in technology, we anticipate robust growth in the mRNA synthesis and manufacturing market.

Key Market Segments

Type of Product

Drug Substance (APIs)

Drug Product (FDFs)

Application Area

mRNA-based Vaccines

mRNA-based Therapeutics

Therapeutic Area

Infectious Diseases

Oncological Disorders

Other Diseases

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

An overview of structure and the historical evolution of mRNA vaccines. A comprehensive discussion pertaining the information on the synthetic mRNA production, both chemically and in vitro, and its applications across various therapeutic area. Further, it features the challenges associated with the synthesis and manufacturing processes of mRNA are outlined as well. Further, the module delves into the commonly outsourced manufacturing operations and their advantages.

A comprehensive evaluation of mRNA custom synthesis service providers, considering several relevant parameters, such as year of establishment, company size (measured by the number of employees), headquarters location (North America, Europe, and Asia Pacific), types of services offered (such as mRNA modification, purification, scale-up, process development, and fill/finish), starting material (plasmid DNA, mRNA sequence, PCR fragments), structural modification (5' modification, 3' modification, ribonucleotide base modification, and others), purification methods (chromatography, electrophoresis, desalting/precipitation, and others), application areas (vaccine production, therapeutic production, and others), and scale of operation (preclinical/research, clinical, and commercial). Additionally, the chapter includes information on the length of the mRNA manufactured and the production capacity of the stakeholders.

An in-depth competitiveness analysis of mRNA custom synthesis service providers across key geographical regions. This analysis takes into account the supplier strength, including years of experience and company size, as well as service strength, which encompasses the number and types of services offered, modifications, scale of operation, compliance with Good Manufacturing Practices (GMP), and application areas.

A thorough assessment of mRNA contract manufacturing service providers, considering various pertinent parameters. These parameters include the year of establishment, company size (measured by the number of employees), headquarters location (North America, Europe, and Asia Pacific), location of manufacturing facilities, types of additional services offered (such as formulation development, analytical testing, process development, mRNA purification, fill / finish, scale-up, regulatory support, and others), type of product manufactured (drug substances (APIs) and drug products (FDFs)), and scale of operation (preclinical/research, clinical, and commercial).

A thorough company competitiveness analysis of mRNA contract manufacturing service providers across key geographical regions, focusing on the supplier strength and service portfolio strength. Supplier strength is assessed based on years of experience and company size, while service portfolio strength considers factors such as the number of facilities, type of products manufactured, variety of services offered, and scale of operation.

A comprehensive evaluation of the current market landscape of mRNA synthesis kits, considering various pertinent parameters. These parameters include kit components (such as enzyme mix, reagents, buffer, etc.), types of enzymes utilized (including capping enzyme and tailing enzyme), enzyme mix variants (such as T7 polymerase, SP6 polymerase, and T3 polymerase), mRNA components modified (cap, base, and tail), number of reactions per kit (ranging from 5 to 50 reactions), yield per reaction (categorized by microgram ranges), reaction run time (classified by duration), and kit price (grouped into price ranges). Furthermore, the chapter provides an extensive analysis of mRNA synthesis kit providers, offering insights into their year of establishment, company size (measured by employee count), headquarters location, and the most active players in terms of the number of mRNA synthesis kits offered.

A detailed analysis of mRNA synthesis kits, focusing on the supplier strength and product attributes. Supplier strength is evaluated based on years of experience and company size, while product strength is assessed based on the number of kit components, types of enzymes included, types of mRNA components modified, yield per reaction, number of reactions per kit, reaction run time, and kit price.

Detailed company profiles of the top mRNA manufacturing companies based on their robust service offerings. Each profile includes a concise company overview, encompassing establishment year, headquarters location, employee count, and notable executives. Additionally, it delves into their mRNA synthesis and manufacturing services, recent advancements, and well-informed future perspectives. Further, the leading service providers in mRNA synthesis and manufacturing, profiles of other noteworthy players have been included, featuring company background and mRNA synthesis and manufacturing service details.

Comprehensive profiles of leading mRNA synthesis kit providers have been curated, selected for their robust product portfolios. Each profile provides a succinct company overview, coupled with details on their mRNA synthesis kits portfolio.

An exhaustive examination of partnerships formed among stakeholders within this industry between 2019 and 2023, taking into account various parameters. These parameters include the year of partnership, nature of partnership, product type, partner type, and identification of the most prolific players based on the quantity of partnerships forged. Furthermore, the analysis offers insights into the regional distribution of the companies engaged in these collaborations.

A comprehensive analysis of over 35 developers of mRNA-based therapeutics and vaccines, identified for potential partnerships with mRNA contract manufacturing service providers. These developers have been carefully shortlisted based on various parameters including the strength of the developer (evaluated through company experience), company size (measured by the number of employees), pipeline robustness (assessed by the quantity of mRNA-based drugs in the pipeline), highest development phase attained, therapeutic focus, route of administration, and the type of candidates under development.

An comprehensive examination of the diverse mRNA-focused initiatives undertaken by major pharmaceutical companies, selected based on their 2023 revenues. This review highlights trends across multiple parameters, including the quantity of initiatives, initiation year, purpose, type, and therapeutic focus of each initiative.

A detailed analysis on the factors influencing the growth of the mRNA synthesis and manufacturing market. This study includes the identification and examination of key drivers propelling market expansion, potential restraints hindering growth, emerging opportunities for market advancement, and existing challenges that may impede progress.

In-depth forecast analysis of the mRNA synthesis and manufacturing market to estimate both the current market size and the future opportunities up to the year 2035. Utilizing multiple parameters such as anticipated adoption trends and rigorous primary validations, we have derived an informed estimate of the market evolution during the forecast period from 2024 to 2035. Furthermore, this module outlines the likely distribution of the current and forecasted opportunities within the mRNA synthesis and manufacturing market. To enhance the robustness of our model and to accommodate future uncertainties, we have developed three forecast scenarios: conservative, base, and optimistic. These scenarios represent different trajectories of industry growth, providing a comprehensive perspective on potential market developments.

Detailed projections have been formulated for the current and future mRNA synthesis and manufacturing market, categorized by type of product, encompassing both drug substances and drug products. These projections offer comprehensive insights into the anticipated growth trajectories, market sizes, and emerging trends for each product type within the mRNA synthesis and manufacturing landscape.

Detailed projections of the current and future mRNA synthesis and manufacturing market across application area, such as mRNA-based vaccines and mRNA-based therapeutics.

Detailed projections of the current and future mRNA synthesis and mRNA manufacturing market across therapeutic area, such as infectious diseases, oncological disorders and other disorders.

Detailed projections of the current and future mRNA synthesis and manufacturing market across key geographies, such as North America, Europe, Asia-Pacific, and Rest of the World.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the mRNA Synthesis and Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Aldevron

APExBIO

Aurigene Pharmaceutical Services

Biomay

CELLSCRIPT

Curia

eTheRNA

Enzynomics

Eurogentec

Genscript

Jena Bioscience

Merck KGaA

New England Biolabs

Vernal Biosciences

ST Pharm

Thermo Fisher Scientific

TriLink BioTechnologies

WuXi Biologics

TABLE OF CONTENTS

1. PREFACE

• 1.1. mRNA Synthesis and mRNA Manufacturing Market
• 1.2. Market Share Insights
  • 1.2.1. Market Segmentation Overview
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Overview of mRNA
• 5.2. Structure of mRNA
• 5.3. Evolution of mRNA Vaccines
• 5.4. Steps involved in mRNA Synthesis
  • 5.4.1. Chemical Synthesis of mRNA
  • 5.4.2. In vitro Synthesis of mRNA
• 5.5. Applications of Chemical/ in vitro Synthesized mRNA
• 5.6. Challenges Associated with mRNA Synthesis
• 5.7. mRNA Contract Manufacturing
  • 5.7.1. Commonly Outsourced mRNA Manufacturing Operations
  • 5.7.2. Advantages of Outsourcing Manufacturing Operations

6. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE

• 6.1. mRNA Custom Synthesis Service Providers: Market Landscape
  • 6.1.1. Analysis by Year of Establishment
  • 6.1.2. Analysis by Company Size
  • 6.1.3. Analysis by Location of Headquarters
  • 6.1.4. Analysis by Type of Service Offered
  • 6.1.5. Analysis by Starting Material
  • 6.1.6. Analysis by Structural Modification
  • 6.1.7. Analysis by Type of Purification Method
  • 6.1.8. Analysis by Application Area
  • 6.1.9. Analysis by Scale of Operation
  • 6.1.10. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Synthesized
  • 6.1.11. mRNA Custom Synthesis Service Providers: Information on mRNA Production Capacity

7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Methodology
• 7.3. Scoring Criteria
• 7.4. mRNA Custom Synthesis Service Providers: Company Competitiveness Analysis
  • 7.4.1. mRNA Custom Synthesis Service Providers based in North America
  • 7.4.2. mRNA Custom Synthesis Service Providers based in Europe
  • 7.4.3. mRNA Custom Synthesis Service Providers based in Asia-Pacific

8. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

• 8.1. Chapter Overview
• 8.2. Detailed Company Profiles of Leading Service Providers
  • 8.2.1. Aldevron
    • 8.2.1.1. Company Overview
    • 8.2.1.2. mRNA Custom Synthesis Service Portfolio
    • 8.2.1.3. Recent Developments and Future Outlook
  • 8.2.2. TriLink BioTechnologies
    • 8.2.2.1. Company Overview
    • 8.2.2.2. mRNA Custom Synthesis Service Portfolio
    • 8.2.2.3. Recent Developments and Future Outlook
  • 8.2.3. eTheRNA
    • 8.2.3.1. Company Overview
    • 8.2.3.2. mRNA Custom Synthesis Service Portfolio
    • 8.2.3.3. Recent Developments and Future Outlook
• 8.3. Short Profiles of Other Prominent Custom Service Providers
  • 8.3.1. Biomay
    • 8.3.1.1. Company Overview
    • 8.3.1.2. mRNA Custom Synthesis Service Portfolio
  • 8.3.2. Genscript
    • 8.3.2.1. Company Overview
    • 8.3.2.2. mRNA Custom Synthesis Service Portfolio
  • 8.3.3. Aurigene Pharmaceutical Services
    • 8.3.3.1. Company Overview
    • 8.3.3.2. mRNA Custom Synthesis Service Portfolio

9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

• 9.1. mRNA Contract Manufacturing Service Providers: Market Landscape
  • 9.1.1. Analysis by Year of Establishment
  • 9.1.2. Analysis by Company Size
  • 9.1.3. Analysis by Location of Headquarters (Region)
  • 9.1.4. Analysis by Location of Headquarters (Country)
  • 9.1.5. Analysis by Location of Manufacturing Facility
  • 9.1.6. Analysis by Type of Additional Services
  • 9.1.7. Analysis by Type of Product Manufactured
  • 9.1.8. Analysis by Scale of Operation

10. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

• 10.1. Chapter Overview
• 10.2. Assumptions and Methodology
• 10.3. Scoring Criteria
• 10.4. mRNA Contract Manufacturing Service Providers: Company Competitiveness Analysis
  • 10.4.1. mRNA Contract Manufacturing Service Providers based in North America
  • 10.4.2. mRNA Contract Manufacturing Service Providers based in Europe
  • 10.4.3. mRNA Contract Manufacturing Service Providers based in Asia-Pacific

11. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

• 11.1. Chapter Overview
• 11.2. Detailed Company Profiles of Leading Service Providers
  • 11.2.1. Eurogentac
    • 11.2.1.1. Company Overview
    • 11.2.1.2. mRNA Contract Manufacturing Services Portfolio
    • 11.2.1.3. Recent Developments and Future Outlook
  • 11.2.2. WuXi Biologics
    • 11.2.2.1. Company Overview
    • 11.2.2.2. mRNA Contract Manufacturing Services Portfolio
    • 11.2.2.3. Recent Developments and Future Outlook
  • 11.2.3. Merck
    • 11.2.3.1. Company Overview
    • 11.2.3.2. mRNA Contract Manufacturing Services Portfolio
    • 11.2.3.3. Recent Developments and Future Outlook
• 11.3. Short Profiles of Other Prominent Service Providers
  • 11.3.1. ST Pharm
    • 11.3.1.1. Company Overview
    • 11.3.1.2. mRNA Contract Manufacturing Services Portfolio
  • 11.3.2. Vernal Biosciences
    • 11.3.2.1. Company Overview
    • 11.3.2.2. mRNA Contract Manufacturing Services Portfolio
  • 11.3.3. Curia
    • 11.3.3.1. Company Overview
    • 11.3.3.2. mRNA Contract Manufacturing Services Portfolio

12. mRNA SYNTHESIS KIT PROVIDERS: MARKET LANDSCAPE

• 12.1. mRNA Synthesis Kits: Market Landscape
  • 12.1.1. Analysis by Kit Components
  • 12.1.2. Analysis by Type of Enzyme
  • 12.1.3. Analysis by Type of Enzyme Mix Used
  • 12.1.4. Analysis by mRNA Component Modified
  • 12.1.5. Analysis by Number of Reaction
  • 12.1.6. Analysis by Yield per Reaction
  • 12.1.7. Analysis by Reaction Run-time
  • 12.1.8. Analysis by Kit Price
  • 12.1.9. Most Active Players: Analysis by Number of Kits Offered
• 12.2. mRNA Synthesis Kits: Providers Landscape
  • 12.2.1. Analysis by Year of Establishment
  • 12.2.2. Analysis by Company Size
  • 12.2.3. Analysis by Location of Headquarters

13. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS

• 13.1. Chapter Overview
• 13.2. Assumptions and Methodology
• 13.3. Scoring Criteria
• 13.4. mRNA Synthesis Kits: Product Competitiveness Analysis

14. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS

• 14.1. Chapter Overview
• 14.2. Jena Biosciences
  • 14.2.1. Company Overview
  • 14.2.2. mRNA Synthesis Kits Portfolio
• 14.3. APExBIO
  • 14.3.1. Company Overview
  • 14.3.2. mRNA Synthesis Kits Portfolio
• 14.4. Thermo Fisher Scientific
  • 14.4.1. Company Overview
  • 14.4.2. mRNA Synthesis Kits Portfolio
• 14.5. CELLSCRIPT
  • 14.5.1. Company Overview
  • 14.5.2. mRNA Synthesis Kits Portfolio
• 14.6. New England Biolabs
  • 14.6.1. Company Overview
  • 14.6.2. mRNA Synthesis Kits Portfolio
• 14.7. Enzynomics
  • 14.7.1. Company Overview
  • 14.7.2. mRNA Synthesis Kits Portfolio

15. PARTNERSHIPS AND COLLABORATIONS

• 15.1. Partnership Models
• 15.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
  • 15.1.1. Analysis by Year of Partnership
  • 15.1.2. Analysis by Type of Partnership
  • 15.1.3. Analysis by Year and Type of Partnership
  • 15.1.4. Analysis by Type of Product
  • 15.1.5. Analysis by Type of Partner
  • 15.1.6. Most Active Players: Analysis by Number of Partnerships
  • 15.1.7. Analysis by Geography
    • 15.1.7.1. Intracontinental and Intercontinental Deals
    • 15.1.7.2. Local and International Deals

16. LIKELY PARTNER ANALYSIS

• 16.1. Methodology and Key Parameters
• 16.2. Scoring Criteria
• 16.3. mRNA Drug Developers: Likely Partners based in North America
  • 16.3.1. mRNA Drug Developers: Most Likely Partners based in North America
• 16.4. mRNA Drug Developers: Likely Partners based in Europe
  • 16.4.1. mRNA Drug Developers: Most Likely Partners based in Europe
• 16.5. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
  • 16.5.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

17. BIG PHARMA INITIATIVES

• 17.1. Analysis Methodology
• 17.2. Scoring Criteria
• 17.3. Big Pharma Players: mRNA- focused Initiatives
• 17.4. Competitive Benchmarking of Big Pharma Players

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 18.1. Chapter Overview
• 18.2. Market Drivers
• 18.3. Market Restraints
• 18.4. Market Opportunities
• 18.5. Market Challenges

19. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Forecast Methodology
• 19.3. Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 19.3.1. Scenario Analysis
• 19.4. Key Market Segmentations

20. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Forecast Methodology
• 20.3. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024 and 2035
  • 20.3.1. mRNA Synthesis and Manufacturing: Market for Drug Substances (APIs), till 2035 (USD Billion)
  • 20.3.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), till 2035 (USD Billion)

21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Forecast Methodology
• 21.3. mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024 and 2035
  • 21.3.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035 (USD Billion)
  • 21.3.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035 (USD Billion)

22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Forecast Methodology
• 22.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2023 and 2035
  • 22.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035 (USD Billion)
  • 22.3.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035 (USD Billion)
  • 22.3.3 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035 (USD Billion)

23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Forecast Methodology
• 23.3. mRNA Synthesis and Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2024 and 2035
  • 23.3.1 mRNA Synthesis and Manufacturing Market in North America, till 2035 (USD Billion)
  • 23.3.2. mRNA Synthesis and Manufacturing Market in Europe, till 2035 (USD Billion)
  • 23.3.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
  • 23.3.4. mRNA Synthesis and Manufacturing Market in Latin America, till 2035 (USD Billion)
  • 23.3.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
  • 23.3.6. mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035, USD Billion

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Canvax
  • 24.2.1. Company Snapshot
  • 24.2.2. Interview Transcript: Bernardo Jose Gomez Fernandez, Business Development Manager
• 24.3. GC Pharma
  • 24.3.1. Company Snapshot
  • 24.3.2. Interview Transcript: Jaehoon Moon, Team Leader
• 24.4 Tebubio
  • 24.4.1. Company Snapshot
  • 24.4.2. Interview Transcript: Jean-Francois, Chief Commercial Officer

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS